Mounjaro retains No. 1 position as 25 leading pharma brands register double-digit growth in May 2026: Pharmarack

The Indian Pharmaceutical Market (IPM) sustained its growth momentum in May 2026, with several leading brands registering strong double-digit growth and reinforcing demand across chronic, acute, and specialty therapy segments. Mounjaro from Eli Lilly retained its position as the No. 1 brand in the IPM at both MAT May 2026 and monthly levels. The brand recorded monthly sales of Rs 109 crore and delivered an exceptional 378.9 per cent value growth over May 2025, while volumes grew by 10.8 per cent, highlighting the continued expansion of the GLP-1 therapy segment, according to the latest monthly report from Pharmarack Technologies.

Among the top-performing brands for May 2026, Glycomet GP (USV) ranked second with monthly sales of Rs 84 crore, reporting 14.4 per cent value growth and 3.0 per cent volume growth. Pan (Alkem) secured the third position with sales of Rs 77 crore, registering 9.9 per cent value growth and 5.1 per cent volume growth. Foracort (Cipla) ranked fourth with 14.7 per cent value growth, although volumes declined by 3.0 per cent. Zerodol SP (Ipca), the fifth-largest brand during the month, posted a robust 27.9 per cent value growth and 19.3 per cent volume growth.

A review of the top 40 brands by monthly sales shows that 25 brands recorded double-digit value growth in May 2026, underscoring the broad-based strength of the pharmaceutical market. Of these, 18 brands also achieved double-digit volume growth, indicating that demand-led expansion remained a key driver of market performance.

Among the leading brands, several delivered strong gains in both value and volume during the month. Cilacar reported 33.2 per cent value growth and 20.0 per cent volume growth, while Budecort grew 30.4 per cent in value and 24.0 per cent in volume. Chymoral Forte recorded 30.4 per cent value growth and 19.1 per cent volume growth, Levera posted 22.6 per cent value growth and 19.5 per cent volume growth, and Gabapin NT achieved 25.9 per cent value growth alongside 17.8 per cent volume growth.

Other prominent brands posting double-digit growth in both value and volume included Telma (14.2 per cent value growth, 12.4 per cent volume growth), Duolin (10.7 per cent, 9.9 per cent), Manforce (20.2 per cent, 19.5 per cent), Levipil (16.2 per cent, 13.1 per cent), Lantus (12.4 per cent, 11.0 per cent), Dytor (17.4 per cent, 16.3 per cent) and Ecosprin AV (31.8 per cent, 7.4 per cent).

Commenting on the market performance, Sheetal Sapale, Vice President – Commercial at Pharmarack Technologies, said "The May 2026 performance reflects sustained momentum across the Indian Pharmaceutical Market, with a significant proportion of leading brands registering double-digit growth. The continued leadership of Mounjaro, along with strong performances from established chronic and acute therapy brands, indicates healthy demand expansion and broad-based market growth. The strong volume growth seen across many leading brands further highlights the underlying strength of prescription demand and patient uptake across therapies."

Key May 2026 Highlights

• No. 1 Brand: Mounjaro (Rs 109 crore)
• Top 5 Brands by May 2026 Sales: Mounjaro, Glycomet GP, Pan, Foracort, Zerodol SP
• Top 40 brands with double-digit value growth: 25 brands
• Top 40 brands with double-digit value and unit growth: 18 brands
• Fastest-growing major brand: Mounjaro (378.9 per cent value growth)
• Strong double-digit value and unit growers: Zerodol SP, Cilacar, Telma, Budecort, Levera, Gabapin NT, Manforce, Lantus, Duolin, Ecosprin AV and others.

Narayan Kulkarni  

Narayan.Kulkarni@mmactiv.com